Evidence map›Paper›PMID 39119882›Full record

ArticleEuropean journal of heart failure2024

Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT-CHF (European) study with the ASIAN-HF registry.

Thong Huy Cao, Wan Ting Tay, Donald J L Jones, John G F Cleland, Jasper Tromp, Johanna Elisabeth Emmens, Tiew-Hwa Katherine Teng, Chanchal Chandramouli, Oliver Charles Slingsby, Stefan D Anker and 12 more

Abstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Thong Huy CaoDepartment of Cardiovascular Sciences, College of Life Sciences, University of Leicester, Leicester, UK.ORCID https://orcid.org/0000-0002-6559-0836
Wan Ting TayNational Heart Centre Singapore and Duke-National University of Singapore, Singapore, Singapore.
Donald J L JonesDepartment of Cardiovascular Sciences, College of Life Sciences, University of Leicester, Leicester, UK.
John G F ClelandBritish Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Health, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Jasper TrompNational Heart Centre Singapore and Duke-National University of Singapore, Singapore, Singapore.
Johanna Elisabeth EmmensDepartment of Cardiology, University of Groningen, Groningen, The Netherlands.ORCID https://orcid.org/0000-0001-9217-956X
Tiew-Hwa Katherine TengNational Heart Centre Singapore and Duke-National University of Singapore, Singapore, Singapore.
Chanchal ChandramouliNational Heart Centre Singapore and Duke-National University of Singapore, Singapore, Singapore.
Oliver Charles SlingsbyDepartment of Cardiovascular Sciences, College of Life Sciences, University of Leicester, Leicester, UK.
Stefan D AnkerDivision of Cardiology and Metabolism, Department of Cardiology (CVK), and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.
Kenneth DicksteinUniversity of Bergen, Stavanger University Hospital, Stavanger, Norway.
Gerasimos FilippatosDepartment of Cardiology, Heart Failure Unit, Athens University Hospital Attikon, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Chim C LangDivision of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
Marco MetraInstitute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Piotr PonikowskiDepartment of Heart Diseases, Wroclaw Medical University and Cardiology Department, Military Hospital, Wroclaw, Poland.
Nilesh J SamaniDepartment of Cardiovascular Sciences, College of Life Sciences, University of Leicester, Leicester, UK.
Dirk J Van VeldhuisenDepartment of Cardiology, University of Groningen, Groningen, The Netherlands.
Faiez ZannadInserm CIC 1433, Université de Lorrain, Nancy, France.
Inder S AnandDepartment of Medicine, University of Minnesota Medical School and VA Medical Center, Minneapolis, MN, USA.ORCID https://orcid.org/0000-0003-1308-4963
Carolyn S P Lam *National Heart Centre Singapore and Duke-National University of Singapore, Singapore, Singapore.ORCID https://orcid.org/0000-0003-1903-0018
Adriaan A VoorsDepartment of Cardiology, University of Groningen, Groningen, The Netherlands.ORCID https://orcid.org/0000-0002-5417-4415
Leong L NgDepartment of Cardiovascular Sciences, College of Life Sciences, University of Leicester, Leicester, UK.ORCID https://orcid.org/0000-0002-6553-5749

Funding

European Commission FP7-242209-BIOSTAT-CHF; EudraCT 2010-020808-29
6 · The paper itself

Abstract

aimsWe investigated the prevalence, clinical characteristics, and prognosis of patients with heart failure (HF) with improved ejection fraction (HFimpEF). METHODS AND

resultsWe used data from BIOSTAT-CHF including patients with a left ventricular ejection fraction (LVEF) ≤40% at baseline who had LVEF re-assessed at 9 months. HFimpEF was defined as a LVEF >40% and a LVEF ≥10% increase from baseline at 9 months. We validated findings in the ASIAN-HF registry. The primary outcome was a composite of time to HF rehospitalization or all-cause mortality. In BIOSTAT-CHF, about 20% of patients developed HFimpEF, that was associated with a lower primary event rate of all-cause mortality (hazard ratio [HR] 0.52, 95% confidence interval [CI] 0.28-0.97, p = 0.040) and the composite endpoint (HR 0.46, 95% CI 0.30-0.70, p < 0.001) compared with patients who remained in persistent HF with reduced ejection fraction (HFrEF). The findings were similar in the ASIAN-HF (HR 0.40, 95% CI 0.18-0.89, p = 0.024, and HR 0.29, 95% CI 0.17-0.48, p < 0.001). Five independently common predictors for HFimpEF in both BIOSTAT-CHF and ASIAN-HF were female sex, absence of ischaemic heart disease, higher LVEF, smaller left ventricular end-diastolic and end-systolic diameter at baseline. A predictive model combining only five predictors (absence of ischaemic heart disease and left bundle branch block, smaller left ventricular end-systolic and left atrial diameter, and higher platelet count) for HFimpEF in the BIOSTAT-CHF achieved an area under the curve of 0.772 and 0.688 in the ASIAN-HF (due to missing left atrial diameter and platelet count).

conclusionsApproximately 20-30% of patients with HFrEF improved to HFimpEF within 1 year with better clinical outcomes. In addition, the predictive model with clinical predictors could more accurately predict HFimpEF in patients with HFrEF.

Indexed as

Heart FailureRegistriesStroke VolumeVentricular Function, LeftAgedEuropeFemaleHumansMaleMiddle AgedPrognosisClinical outcomeHeart failureHeart failure with improved ejection fractionHeart failure with reduced ejection fractionLeft ventricular ejection fractionPredictive modelPredictor

Identifiers

PMID39119882
PMCPMC11683861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.